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Abstract: The Piroplasmida order comprises parasitic protozoa including the Theileria and Babesia species that are transmitted by
vector ticks and can cause severe diseases in domestic and wild animals. Because of limited therapies and available drug resistance,
the discovery of new, effective, and safer drugs for veterinary use is important. Mitogen-activated protein kinases (MAPK) are a group
of serine-threonine protein kinases found in diverse species, including animals and protozoa that conduct vital cellular functions.
Therefore, they have been at the centre of drug design studies for many years. Computer-aided structure-based drug design is a fast and
effective way in drug discovery efforts to identify candidate compounds. In this study, we conducted comparative sequence analysis of
MAPK proteins from the Theileria (T. annulata, T. parva., T. orientalis, and T. equi) and Babesia species (B. bigemina, B. microti, and
B. bovis). Three-dimensional protein structures from relevant species (T. annulata and B. bovis) were modelled and compounds were
screened for interaction. Results showed that the inhibitors designed for human use could also be potent against Prioplasmida MAPKs.
Furthermore, the structural differences between Prioplasmida and mammalian MAPKs could be a way for researchers to better instigate
selective drug design.
Key words: Mitogen-activated protein kinase, computer-aided drug design, theileriosis, babesiosis

1. Introduction
The Theileria and Babesia species (Order Piroplasmida)
are unicellular protozoan parasites belonging to the
phylum Apicomplexa that exhibit characteristic apical
complex and apicoplast organelles. Apicomplexans are
responsible for serious diseases such as toxoplasmosis
(Toxoplasma gondii) and malaria in humans
(Plasmodium falciparum); furthermore, theileriosis
and babesiosis, mainly found in in domestic and farm
animals, account for many deaths, cause a decline in the
quality of life, decrease efficiency, and cause economic
losses. Theileria parva and T. annulata cause East Coast
fever and Tropical theileriosis, respectively, and occur
in a wide range of geographical regions, including
Africa, southern Europe, and Asia. The Babesia species
is spread across southern Europe, Africa, America,
Asia, and Australia and infects buffaloes, deer, sheep,
cattle, and also humans [1–3]. Due to its resistance to
buparvaquone, a conventionally used drug to treat
theileriosis, and because of limited therapies in bovine
babesiosis because of drug residues in by-products (milk
and meat) and toxicity, it is necessary to discover safer
and more effective and medications [4–8].

The MAPK signalling cascade is essential and regulates
numerous cellular functions in eukaryotes such as
proliferation, differentiation, development, inflammation,
cell death, and stress response. They are phosphorylated
by upstream MAP4Ks, MAP3Ks, and MAPKKs and turn
on specific MAPKs terminated by the phosphorylation
of nuclear factors and other kinases as cytosolic targets
[9]. The MAPK family is classified under the cell cycle
associated kinase (CMGC) group, along with 7 other
families, including cyclin-dependent kinases (CDK),
glycogen synthase kinases (GSK), and Cdk-like kinases
(CLK) in humans [10].
Piroplasms have the smallest protein kinome size
(there are only 42 protein kinases in T. annulata)
compared to other organisms in Apicomplexa [11,12].
MAPK family proteins are presented in low numbers in
all apicomplexans and found in only 2 members: Theileria
and Babesia [11,13]. The absence of the entire STE group
of serine/threonine protein kinases, joined to the MAPK
signalling cascade in most eukaryotes, point to a unique
signalling mechanism for apicomplexans [11]. There are
many studies indicating the various roles of the MAPKs
of protozoan parasites, some of which include ERK1
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and ERK2 of Giardia spp. in encystation [14], MAPK2s
of P. falciparum and P. berghei in the asexual cell cycle
[15], and male gametocide formation [16], respectively.
Moreover, various cellular functions in the Leishmania
and Trypanosoma species have been reported, such as
drug resistance, survival, proliferation, flagellum length
control, and differentiation [17–20]. Along with other
protein kinases, the MAPKs of protozoans are therefore
attractive drug targets for the treatment of animal diseases
[21,22].
Like other closely related apicomplexans, piroplasms
have MAPKs like ERK7/8 (MAPK-15), designated as
MAPK1 (MAPK2 in T. gondii), which carry a T(D)
Y motif conserved in the activation loop [11,13,22].
However, the other MAPK, called MAPK2 (MAPK3 in
T. gondii), is classified as an atypical MAPK with a TGH
motif in the activation loop of T. gondii and piroplasms
(TSH in P. falciparum) [13,21,22]. Their unique structural
and functional features, compared to their mammalian
counterparts and their evolutionary distance, make
apicomplexan MAPKs attractive, druggable proteins, and
this paves the way for selective drug design [13,21,23].
The main aim of this study is to repurpose the
validated MAPK inhibitors, which were previously
designed to combat human diseases on Theileria and
Babesia MAP kinase 1 and 2 by computational structural
biology approaches. This is the first report consisting of
genome-wide screening of MAPK genes of piroplasms
in detail with structural modelling, molecular dynamics
analysis, and docking on Theileria and Babesia MAPK1
and MAPK2 proteins.
2. Material and methods
2.1 Sequence retrieval and analysis
Mitogen-activated protein kinase 2 sequences from T.
annulata (Ankara str.), T. orientalis (Shintoku str.), T. parva
(Muguga str.), and T. equi (WA str.) were retrieved from the
NCBI RefSeq database. Sequences belonging to MAPK1s
from both the Theileria and Babesia species [B. bigemina, B.
microti (RI str.), and B. bovis (T2Bo str.)] and the MAPK2
of the Babesia species were predicted by DELTA-BLAST
from NCBI (blast.ncbi.nlm.nih.gov) and BLASTP from the
Ensembl Protist genome database (http://protists.ensembl.
org) using P. falciparum 3D7 MAPK1 (XP_001348468.1)
and MAPK2 (XP_001347818.1) as reference protein
sequences. Resultant sequences were further confirmed
by the Conserved Domain Database (CDD) from NCBI
[24] and Pfam (protein families database) 32.0 [25] for
an exact MAP kinase domain explication. Homologous
sequences of MAPK1 and MAPK2 from the host species
Homo sapiens and Bos taurus and the other apicomplexans
(T. gondii and Cryptosporidium parvum) were identified by
BLASTP search against RefSeq database using an E-value
threshold of 1 × 10–10.

MAPK1 and MAPK2 sequences from the
Theileria and Babesia species and H. sapiens MAPK15
(NP_620590.2), MAPK11 (NP_002742) and MAPK14
(NP_001306.1), B. taurus MAPK15 (NP_001039575.1),
MAPK11
(NP_001073804.1)
and
MAPK14
(NP_001095644.1), T. gondii ERK7 (XP_018636795.1)
and MAPK3 (XP_002369585.1), and C. parvum MAPK2
(XP_001388246.1) sequences were analysed for conserved
residues and divergences by applying multiple sequence
analysis using the T-COFFEE multiple sequence alignment
program [26]. Multiple sequence alignments were
visualized on an ESPript 3.0 server [27]. Pairwise sequence
alignments were conducted using the EMBOSS-water
tool [28]. Phylogenetic relationships of MAPKs among
apicomplexans were assigned via MEGA7 software
[29] using the neighbor-joining method employing 500
bootstrap replications. Motifs within MAPK sequences
were predicted and analysed by a MEME (Multiple Em
for Motif Elicitation) server in MEME suite 5.1.0 [30].
Predictions of disordered regions were conducted by
applying a false positive rate of 5% using a PrDOS server
[31].
2.2. Comparative modelling and validation
A comparative modelling of the MAPK1 and MAPK2
structures from T. annulata and B. bovis was conducted
with a Modeller 9.16 program [32] using template PDB files
identified by BLASTP search against the PDB database,
pairwise sequence alignment, and MAPK amino acid
sequences. After the modelling process, potential energy
was minimized by applying 2000 and 1000 steps of steepest
descent and conjugate gradient algorithm, respectively,
using the AMBERff14SB force field from Chimera 1.10.2
program [33]. Minimized structures were validated by
ERRAT [34], ProSA [35], ProQ [36], and RAMPAGE
[37] servers to attain 3D-model quality. Superimpositions
and RMSD calculations based on C-alpha traces between
models and templates were done in PyMOL 2.2.0 (PyMOL
Molecular Graphics System, Ver. 2.0 (Schrödinger, NY,
USA). Druggability assessment of protein cavities was
predicted by a DoGSiteScorer server [38].
2.3. Molecular dynamics simulations and docking
The molecular dynamics of the MAPK1 and MAPK2
proteins of T. annulata and B. bovis were assessed by
all-atom molecular dynamics simulations by using the
NAMD 2.9 program [39] and the CHARMM force field.
Structures were prepared within a water box and analysed
after the MD simulations in the VMD 1.9.3 program
[40] for RMSD and RMSF values. Initially, the first 2500
steps of the total 5000 steps of energy minimisation were
conducted, wherein, at first, the protein structures were
fixed; following this, the whole system was allowed free
movement. A simulated annealing was applied for the
system so that the temperature would be fixed at 300K in
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NVT conditions. The system was then equilibrated in an
NPT (1-atm pressure and 300 K temperature) ensemble.
Lastly, a final 50 ns of production md simulation was
done in same NPT conditions with 2fs timesteps.
MAPK inhibitors were searched for and downloaded
in the proper file formats from the IUPHAR/BPS Guide
to Pharmacology (http://www.guidetopharmacology.
org). Inhibitor and protein structures were prepared by
LigPrep (Schrödinger, NY, USA) and ProteinPrepWizard,
respectively, in Maestro (Schrödinger, NY, USA) by
applying the OPLS3 force field. ATP binding pockets
of MAPK1 and MAPK2 were selected as the target site,
and receptor grids were defined by the Receptor Grid
Generation module from Glide (Schrödinger, NY, USA).
In total, 38 MAPK inhibitors were docked to the active
site of proteins by applying a 2-tier procedure, wherein,
as a first step, 30% of the best ligands that were selected
by Glide SP docking were analysed further by a Glide XP
docking step (Schrödinger, NY, USA). The top 5 scoring
ligands were further assessed for their MM-GBSA binding
energies in Prime (Schrödinger, NY, USA).
3. Results and discussion
3.1. Sequence retrieval and analysis
Evolutionary analyses of MAPKs from apicomplexans
including T. annulata, T. parva, and B bovis were reported
by Talevich et al. [11,12]. MAPK sequences from other
Theileria and Babesia species were identified in detail by
DELTA-BLAST searches from both NCBI RefSeq and

the Ensembl Protist genome databases (Table 1). Based
on homology, the Theileria and Babesia species contain
2 types of mitogen-activated protein kinases like P.
falciparum, to which MAPK1 is evolutionary related with
the MAPK15-like (ERK7/8) (CDD number: cd07852)
protein; MAPK2 constitutes the “Serine/Threonine Kinase,
Mitogen-Activated Protein Kinase domain” (CDD identity
cd07834) (Table 1) [11,21,22].
According to the sequence analysis, MAPK1s from
both species have an N-terminal kinase domain with a
mean sequence length of 342. However, in the MAPK2
kinase domain located at the C-terminus, the sequence
varies in length (Figures 1–2). When comparing
sequences of piroplasm MAPKs with B. taurus and H.
sapiens MAP kinases, MAPK1 shows homology with the
mammalian MAPK15 (ERK7/8), and p38 MAPK (like
MAPK11, MAPK14) proteins present a higher identity
match with the piroplasm MAPK2. In fact, based on local
alignments of MAPK1s from B. bovis and T. annulata in
humans and cattle, MAPK15 showed about 38% and 48%
identity between MAPK specific domains, respectively. In
contrast, a 32% identity was shown between mammalian
MAPK11 and MAPK2s of both B. bovis and T. annulata
based on conserved kinase domains. Percentage identities
of MAPK1 and MAPK2 vary between species of Theileria
and Babesia. The closest sequences were between T.
annulata and T. parva, whose identities were calculated
at about 70% and 86.5% for MAPK1 and MAPK2,
respectively. Phylogenetic trees also indicate a close

Table 1. Mitogen-activated protein kinases from Theileria and Babesia genomes.

Organism/strain

NCBI protein Name

Assigned as

NCBI Accession

Length

CDD
Kinase
Domain

Theileria annulata/
Ankara

Protein kinase

MAPK1

XP_954104

709

7-354

MAPK2

MAPK2

XP_954376

642

193-624

Theileria orientalis/
Shintoku

Protein kinase

MAPK1

XP_009689510

789

7-365

MAPK2

MAPK2

XP_009689160

620

158-602

Theileria parva/
Muguga

Serine/threonine protein kinase

MAPK1

XP_766199

677

7-351

MAPK2

MAPK2

XP_765886

642

193-624

Theileria equi/
WA

Protein kinase domain containing protein

MAPK 1

XP_004833198

598

5-342

MAPK2

MAPK2

XP_004829898

581

146-563

MAPK

MAPK1

XP_012766705

502

5-342

MAPK

MAPK2

XP_012767953

600

173-582

Extracellular signal-regulated kinase 2

MAPK1

XP_021338713

583

5-341

MAPK

MAPK2

XP_012648003

556

106-537

MAPK

MAPK1

XP_001610969

506

5-342

MAPK

MAPK2

XP_001610481

584

159-566

Babesia bigemina
Babesia microti/
RI
Babesia bovis/ T2Bo

704

MUTLU / Turk J Vet Anim Sci

Figure 1. Multiple-sequence analysis of the MAPK1 proteins of piroplasms with T. gondii MAPK2, P. falciparum MAPK1, B. taurus
MAPK15, and H. sapiens MAPK15 (based on 70% consensus).

relationship between apicomplexan MAPKs (Figures 3A
and 3B). Both MAPK1 and MAPK2 have unstructured
lengthy regions at their C and N-termini, respectively,
and inside the activation loop segment like other MAP
kinases from apicomplexans [21,22]. The multiple
sequence alignment of the MAPK1s with those of other
apicomplexans (P. falciparum and T. gondii) suggests a
consensus on a phosphorylation lip triad located at the
186-TDY-190 position (T. annulata numbering), which
designates the MAPK1 from the Theileria and Babesia
species as a typical MAPK like that of P. falciparum (Figure
1) [22]. On the other hand, MAPK2s from the Theileria

and Babesia species belong to atypical MAPKs, which bear
a phosphorylation lip sequence in the form of a “TGH”
motif, like the atypical MAPK of T. gondii (MAPK3) [13].
However, B. microti MAPK2 bears a triad motif, in the
form of a “TSH”, like the atypical P. falciparum MAPK2
(Figure 2) [21]. The MEME server was used to show motifs
thought sequences (Figures 3C and 3D). Within MAPK1
proteins, there is a consensus across 8 motifs. However, 3
additional motifs were found in apicomplexan MAPK2
sequences, and 2 of them (7 and 8) were located at the
C-terminus of the specific MAPK insertion site and not
found in their mammalian counterparts. Since they have a
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Figure 2. Multiple-sequence analysis of the MAPK2 proteins of piroplasms with T. gondii MAPK3, P. falciparum MAPK2, C. parvum
MAPK2, B. taurus MAPK11 and MAPK14, H. sapiens MAPK11, and MAPK14 (based on 70% consensus).

role in the intrinsic autophosphorylation of a component
of the MAPK insertion site of the mammalian p38-beta
MAPK [41], additional motifs (7 and 8) in apicomplexans
could be considered to be druggable sites for phylumspecific MAPK inhibitors (Figures 4A and 4B)
3.2. Comparative protein modelling and structure
validation
Representative structures of the kinase domains of
MAPK1 and MAPK2 from T. annulata and B. bovis were
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modelled by a comparative approach using a Modeller 9.16
program based on the atomic coordinates of C. parvum
MAPK1 (PDB ID: 3OZ6) and T. gondii MAPK3 (PDB
ID: 3RP9) structures, respectively (Figure 4). MAPK1s
from T. annulata and B. bovis show 56% (Query cover:
49% and E-value: 2e-142) and 52% (Query cover: 67%
and E-value: 1e-137) identity matches with the crystal
structure of C. parvum MAPK1. MAPK2 shows 49%
(Query cover: 77% and E-value: 8e-173) and 57% (Query

MUTLU / Turk J Vet Anim Sci

Figure 3. Phylogenetic relationships among apicomplexan MAPK1 (A) and MAPK2 (B) proteins. MEME motif analysis of MAPK1
from apicomplexans with B. taurus and H. sapiens MAPK15 (C) and MAPK2 with B. taurus and H. sapiens MAPK11 and MAPK14 (D).

cover: 72% and E-value: 4e-169) identity with the crystal
structure of T. gondii MAPK3 for both T. annulata and B.
bovis, respectively. Having a good sequence consensus is a
crucial step for homology model predictions, and higher
identity values make the construction of more accurate
models possible. In this case, kinase domains were
predicted based on templates, which have a mean identity
of 54%, which is suitable for structure-based drug design
and prediction of binding modes of small molecules in
the active site. All generated models were subjected to
geometry optimisation via potential energy minimisation.
Resultant protein structures were further validated for 3D
structure quality, and all structures were shown to have an
adequate grade for further structural studies (Table 2).
Root mean square deviation (RMSD) values that
represent structural similarities to template structures
were found to be 0.697 Å and 0.684 Å for MAPK1s, 0.714
Å and 0.719 Å for MAPK2s for both T. annulata and B.
bovis, respectively. These values are higher than expected
due to the presence of long disordered activation loops in
all structures. The ATP binding pocket is the major drugtargeting site, which has been the subject of many structure-

based drug design efforts [42]. DoGSiteScorer was used to
predict targeting pockets and determine their drugabilities
on MAPK1 and MAPK2 proteins. The server analysis
results showed that the ATP sites have the highest scoring
sites on MAPK structures for drug targeting (Table 2).
3.3. Molecular dynamics simulations and docking
Molecular dynamics of the T. annulata and B. bovis MAPK
1 and 2 were analysed by all-atom molecular dynamics
simulations under NPT (1-atm pressure and 300 K
temperature) conditions for 50 ns. Due to the absence
of any molecular dynamics studies on apicomplexan
MAPKs, structural features were compared with
mammalian MAPK counterparts in this study [42,43].
As seen in Figure 5A, the MAPK1 structures of both B.
bovis and T. annulata were found to be more stable than
MAPK2 proteins, with average RMSD values of 3.05 Å
and 3.78 Å, respectively. The highest RMSD value belongs
to the B. bovis MAPK2, which is unstable and shows
large fluctuations until the 40-ns mark. The disordered
activation loop in MAPK2 is longer than that of MAPK1
proteins. Therefore, fluctuations due to this unstructured
activation loop, especially in BbMAPK2, have been clearly
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Figure 4. Cartoon view of the superimposition of MAPK1 (A) and MAPK2 (B) structures with template proteins of C. parvum
(3OZ6_A) and T. gondii (3RP9_A). Red: templates; Green: T. annulata MAPK1 and MAPK2; Blue: B. bovis MAPK1 and MAPK2;
specific insertions in piroplasm MAPK2 proteins are coloured yellow. A red asterisk shows ATP binding pockets used for the molecular
docking site.
Table 2. Structural validations of MAPK kinase models.
TaMAPK1

TaMAPK2

BbMAPK1

BbMAPK2

ProSA (Z-Score)

–7.87

–7.47

–7.66

–7.98

ProQ (LGScore)*

5.336

4.518

6.019

4.009

ERRAT overall score

93.0556

80.5419

87.7246

78.5714

Favoured region

87.2%

86.6%

88.4%

85.6%

Allowed region

12.0%

11.8%

9.3%

13.2%

Outlier region

0.8%

1.6%

2.3%

1.2%

RMSD**

0.697

0.714

0.684

0.719

DoGSiteScorer DrugScore

0.69

0.82

0.83

0.81

Ramachandran plot scores

*LGscore > 1.5 = fairly good model; LGscore > 2.5 = very good model; LGscore > 4 = extremely
good model.
**RMSD values were calculated for C-alpha traces by superimposing them with template PDB
files.

observed on the RMSF graph between 145–193 amino
acids (Figure 5B, red arrow).
In all MAPKs analysed in this study, large fluctuations
in the activation loop were visible (Figure 5B, red arrow),
and similar results have also been found regarding the
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activation loop thermal mobility in research conducted
on the human p38 MAPK [42,43]. Another feature of
RMSF analysis is the MAPK-specific insertion mobility
in TaMAPK1 and BbMAPK1, which was also seen in
the ERK2 and p38 MAPK (Figure 5B, green arrow) [43].

MUTLU / Turk J Vet Anim Sci

Figure 5. Root mean square deviation (RMSD) (A) and root mean square fluctuation (RMSF) (B) graphs of TaMAPK1 (orange),
TaMAPK2 (yellow), BbMAPK1 (blue), and BbMAPK2 (grey) structures. Red arrow: activation loop; green arrow: MAPK specific
insertion; blue arrow: specific insertion site; purple arrow: C-terminal region.

However, in the case of MAPK2s, the MAPK-specific
insertion site did not show distinct fluctuations, unlike
their mammalian counterparts, while the apicomplexanspecific insertion site shows a high degree of mobility
(Figure 5B, blue arrow). Moreover, the C-tail region,
like those of other MAPKs, showed higher fluctuations
which are thought to have a role in allosteric regulations
in MAP kinases [42–44]. By using the IUPHAR/BPS
Guide to Pharmacology database, we identified 38 active
MAPK kinase (especially p38 MAPK) inhibitors with
the lowest IC50 values and screened MAPK targets via
a 2-tier protocol consisting of the selection of the top
30% best compounds by SP docking and further analysis
through a Glide XP docking step for the best possible
hits (Table 3). Based on screening and molecular docking
results, a compound with the PubChem ID 11714580

(named as PF-03715455) was found in all MAPKs’ ATP
binding sites, 3 of which (except TaMAPK2) had the
highest DeltaG-binding energy. Pose views showed that
the compound of interest interacted with binding pocket
residues and made hydrogen bonds with TaMAPK1
(Ser142, Gly27, and Asp156), BbMAPK1 (Asp98), and
BbMAPK2 (Arg23, Ala92, and Asp133) (Figures 6A, 6B,
and 6D). Furthermore, with TaMAPK2, the compound
formed a pi and a salt-bridge interaction with Tyr6
and Lys24 residues, respectively (Figure 6C). Another
pi interaction also occurred between the 3-chloro-4hydroxyphenyl moiety of the compound and the His100
residue of BbMAPK1.
Compound 11714580 is an investigational, small
chemical currently in phase I trials that belongs to the
pyrazole class and was designed to combat asthma and

709

MUTLU / Turk J Vet Anim Sci
Table 3. Molecular docking results of the MAPK inhibitor library on TaMAPK1 and 2 and BbMAPK1
and 2.
Pubchem ID

Target name

XP GScore

XP HBond

MMGBSA dG Bind

11714580*

–7.501

–1.372

–49.01

156422

–7.498

–1.212

–49.01

25125014**

–7.211

–1.040

–41.27

176167

–6.866

–0.148

–35.81

644241

–6.533

–0.973

–45.93

5228

–5.728

–0.485

–29.40

11714580*

–5.410

–0.434

–11.24

25125014**

–5.012

–0.960

–21.74

11314340

–4.896

–0.645

–21.18

10297982

–4.379

–1.300

–27.17

11314340

–7.077

–1.981

–29.34

11714580*

–6.903

–1.134

–40.97

25125014**

–6.456

–1.440

–35.20

11485656

–5.316

–1.407

–40.28

–4.706

–0.665

–38.94

10297982

–6.458

–0.696

–39.52

11714580*

–5.436

–1.587

–60.59

25125014**

–5.298

–3.095

–14.49

176167

–4.893

–1.560

–32.92

103905584

–4.435

–1.126

–26.38

TaMAPK1

TaMAPK2

BbMAPK1

10297982
BbMAPK2

*Pubchem ID_11714580 and ** Pubchem ID_25125014 compounds were found in all MAPKs.

pulmonary diseases by inhibiting the p38-alpha MAPK
kinase in humans. Functional and structural studies have
shown that the compound bound to the ATP site of human
p38-alfa MAPK with high affinity (KD: 0.001 nM) and
showed preclinical safety properties for human use [45]. The
other compound which interacted with all MAP kinases,
with binding scores worse than 11714580, is 25125014
(BS-194), a pyrazolo[1,5-a]pyrimidine derivative designed
for cancer chemotherapy. It shows potency and selectivity
on human cyclin-dependent protein kinases (1, 2, 7, and
9) and ERK8 (MAPK15) with a low IC50 value (0.33 uM)
[46]. These 2 small molecules, which have potency on
human MAPKs, have interacted with MAPK 1 and 2 in T.
annulata and B. bovis in silico, so further in vitro studies
should be done for a more precise inhibition potential
unravelling. Furthermore, reports have shown that the
inhibitors designed for human MAPKs (especially for p38)
act on apicomplexan organisms, including P. falciparum,
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by blocking replication in human erythrocytes, Eimeria
tenella, kinetoplastid parasite L. donovani, T. gondii, and
the microsporidian parasite Encephalitozoon cuniculi
[47–50]. This indicates a great potential for human MAPK
inhibitors as promising drugs to fight parasitic diseases and
makes a way for an improvement to the current inhibitors
with higher efficiency and safety.
Since the first oncogene was designated as a protein
kinase in 1978, great efforts in drug discovery have been
made on different types of protein kinases. In addition, 13
small chemicals targeting serine/threonine protein kinases
were approved by the FDA for use on human diseases
[51,52]. Due to the pathophysiological roles of MAP
kinases in apicomplexans, they have become molecules of
strong interest in drug development [22,47]. In this study,
we investigated the interaction potencies of MAPK kinase
inhibitors with T. annulata and B. bovis MAPK 1 and 2
protein structures by using integrated computational

MUTLU / Turk J Vet Anim Sci

Figure 6. Molecular docking views of 11714580 (PubChem ID) within the ATP binding pocket of TaMAPK1 (A), BbMAPK1 (B),
TaMAPK2 (C), and BbMAPK2 (D). Yellow and orange dots: H-bonds; cyan dots: pi interactions.

techniques. The results showed that the inhibitors
designed for MAPKs of mammalians also have inhibition
potency on piroplasm MAPKs. However, there is also
an opportunity for selective drug design for piroplasm
MAPKs, which show sequential and structural differences
due to their evolutionary divergence when compared with
their host counterparts.
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